REPL
HEALTHCAREReplimune Group Inc
AI Insight
What's Moving REPL Today?
No stock-specific AI insight has been generated for REPL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.50$13.24
$11.55
Fundamentals
Market Cap$943M
P/E Ratio—
EPS$-3.44
Dividend Yield—
Dividend / Share—
ROE-90.9%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding82.6M
REPL News
25 articles- Replimune Group Inc expected to post a loss of 71 cents a share - Earnings PreviewTradingView·Jun 19, 2026
- Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An EndYahoo Finance·Jun 17, 2026
- Insider Sell: Christopher Sarchi Sells 12,000 Shares of Replimune Group Inc (REPL)GuruFocus·Jun 4, 2026
- REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo DrugYahoo Finance·Jun 1, 2026
- Why Is REPL Stock Gaining In Pre-Market Today?Stocktwits·Jun 1, 2026
- Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingYahoo Finance·May 31, 2026
- Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual MeetingYahoo Finance·May 30, 2026
- Replimune plans third attempt at RP1 approval in coming daysThe Business Journals·May 30, 2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo Finance·May 29, 2026
- REPL Stock Shot Up 80% Today – What’s The Deal With FDA?Stocktwits·May 29, 2026
- Replimune to Resubmit RP1 BLA; FDA to Prioritize Review for Advanced MelanomaTradingView·May 29, 2026
- Market Chatter: Replimune Plans to Resubmit Melanoma Therapy Application for FDA ApprovalYahoo Finance·May 29, 2026
- Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDAYahoo Finance·May 29, 2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionYahoo Finance·May 13, 2026
- Oncolytics Biotech Reports Data in Colorectal Cancer StudyYahoo Finance·May 6, 2026
- Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingYahoo Finance·Apr 27, 2026
- Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA DecisionYahoo Finance·Apr 17, 2026
- Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design ConcernsYahoo Finance·Apr 15, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Apr 13, 2026
- Top Midday DeclinersYahoo Finance·Apr 13, 2026
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low.Yahoo Finance·Apr 13, 2026
- Sector Update: Health Care Stocks Softer Monday AfternoonYahoo Finance·Apr 13, 2026
- Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock CrashesYahoo Finance·Apr 13, 2026
- Replimune melanoma therapy rejected by FDA, shares plungeProactive Investors·Apr 13, 2026
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire Inc.·Apr 10, 2026
All 25 articles loaded
Price Data
Open$11.46
Previous Close$11.42
Day High$11.86
Day Low$11.34
52 Week High$13.24
52 Week Low$1.50
52-Week Range
$1.50$13.24
$11.55
Fundamentals
Market Cap$943M
P/E Ratio—
EPS$-3.44
Dividend Yield—
Dividend / Share—
ROE-90.9%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding82.6M
About Replimune Group Inc
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—